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Background: LEDGF/p75 (LEDGF) is the main cellular cofactor of HIV-1 integrase (IN). It acts as a tethering factor for
IN, and targets the integration of HIV in actively transcribed gene regions of chromatin. A recently developed class
of IN allosteric inhibitors can inhibit the LEDGF-IN interaction.
Results: We describe a new series of IN-LEDGF allosteric inhibitors, the most active of which is Mut101. We determined
the crystal structure of Mut101 in complex with IN and showed that the compound binds to the LEDGF-binding
pocket, promoting conformational changes of IN which explain at the atomic level the allosteric effect of the IN/LEDGF
interaction inhibitor on IN functions. In vitro, Mut101 inhibited both IN-LEDGF interaction and IN strand transfer activity
while enhancing IN-IN interaction. Time of addition experiments indicated that Mut101 behaved as an integration
inhibitor. Mut101 was fully active on HIV-1 mutants resistant to INSTIs and other classes of anti-HIV drugs, indicative that
this compound has a new mode of action. However, we found that Mut101 also displayed a more potent antiretroviral
activity at a post-integration step. Infectivity of viral particles produced in presence of Mut101 was severely decreased.
This latter effect also required the binding of the compound to the LEDGF-binding pocket.
Conclusion: Mut101 has dual anti-HIV-1 activity, at integration and post-integration steps of the viral replication cycle,
by binding to a unique target on IN (the LEDGF-binding pocket). The post-integration block of HIV-1 replication in
virus-producer cells is the mechanism by which Mut101 is most active as an antiretroviral. To explain this difference
between Mut101 antiretroviral activity at integration and post-integration stages, we propose the following model:
LEDGF is a nuclear, chromatin-bound protein that is absent in the cytoplasm. Therefore, LEDGF can outcompete
compound binding to IN in the nucleus of target cells lowering its antiretroviral activity at integration, but not in the
cytoplasm where post-integration production of infectious viral particles takes place.
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Raltegravir (Merck) and Elvitegravir (Gilead) were intro-
duced in 2007 and 2012 respectively, as the first gener-
ation of integrase strand transfer inhibitors (INSTIs) and
confirmed integrase (IN) as a clinically validated viral
target for antiretroviral (ARV) therapy [1]. The mode of
INSTI action was elucidated in complex with a retroviral
IN for which the entire 3D structure was defined [2].
However, resistance to INSTIs has emerged in patients
[3,4]. A second generation of INSTIs, less sensitive to drug-
resistance mutations, has been approved (Dolutegravir
(DTG) from GSK-Shionogi-ViiV). DTG belongs to the
same class of compounds and remains sensitive to the
strongest INSTI resistance mutations [5,6]. This highlights
the need for integration inhibitors with completely
different mechanism of action.
LEDGF/p75 (LEDGF), the main cellular cofactor of IN
[7-9] is of great interest for the development of a novel
generation of integration inhibitors. LEDGF interacts
with IN through its C-terminal integrase binding domain
(IBD). HIV-1 IN catalytic core (IN-CCD) and N-terminal
domains are involved in the interaction with LEDGF
[7-12]. LEDGF is crucial for integration and replication of
HIV [13] although minor residual replication (~10%) was
seen in LEDGF-depleted cells [14]. LEDGF functions as a
tethering factor for IN, targeting the integration of HIV
in actively transcribed gene regions of chromatin [15].
LEDGF binds to the interface of an IN dimer and
promotes IN tetramerization which results in the func-
tional form of IN required for concerted integration
[16]. The elucidation of the 3D structure of the IN-
LEDGF interfaces [11,12], together with the mapping of
the critical residues involved [11,17] suggested the
“druggability” of this target. The results defined a new
IN pharmacophore which is different from the catalytic
site targeted by existing INSTIs. A rational screening
of the 3D structure by Zeger Debyser and colleagues
resulted in the discovery of 2-(quinolin-3-yl) acetic acid
derivatives (termed “LEDGINs”) as inhibitors of IN-
LEDGF interactions [18]. Tert-butoxy-(4-phenyl-quino-
lin-3yl)-acetic acids (tBPQAs), analogues with closely
related structures, have been identified by screening for
inhibition of IN 3’ processing activity [19-22]. These
tBPQAs are also efficient IN-LEDGF inhibitors. Several
analogs to this family of molecules have since had patents
submitted and published [23-34].
Several inhibitory activities of LEDGINs and tBPQAs
have been reported so far. These include the inhibition
of IN-LEDGF interaction, the inhibition of IN strand
transfer and 3′ processing activities (independent of
LEDGF), change in IN oligomerization toward sta-
bilization of IN dimers and inhibition of the formation
of the stable IN-viral DNA synaptic complex (SSC)
[18,35-38]. These compounds are considered as allostericinhibitors of IN that are able to block HIV integration
[18,35-40] and are also referred to as ALLINIs [37,40].
These compounds remain fully active on IN mutants that
are resistant to INSTIs and are therefore a promising
new class of IN inhibitors. An inhibitory effect of LED-
GINs on the infectivity of progeny virions has been
reported lately [35,41-45]. The multiple activities of
these compounds raise questions regarding the unicity
or multiplicity of their mechanism of action. Here, we
explore what mode of action could explain the multiple
activities of these inhibitors. We investigate the respective
contribution of these different activities to the overall
ARV activity of these compounds using a new series of
IN-LEDGF inhibitors from the LEDGIN and tBPQA
family of compounds.
Results
Development of IN-LEDGF allosteric inhibitors
New IN-LEDGF allosteric inhibitors (INLAIs) of the aryl
or heteroaryl-tertbutoxy-acetic acid family were designed.
The structure and activities of 7 of these compounds are
shown on Table 1. These compounds efficiently inhibited
IN-CCD/LEDGF-IBD interaction as well as the interaction
between IN and full length LEDGF proteins in homo-
geneous time-resolved fluorescence (HTRF) assays
(Figure 1A and C). MT4 cells were infected with
HxB2 HIV-1 and a subset of 51 compounds showed a
good correlation between their ARV activity and their
ability to inhibit IN-CCD/LEDGF-IBD or IN-LEDGF
interactions (Figures 1B and D). The most active
compound for IN-LEDGF inhibition, Mut101, also
had the highest ARV activity (an EC50 value of 92 nM
against HxB2 infection, CC50 for cytotoxicity was
undetectable at over 50 μM (Table 1)). LEDGF was
able to compete with these inhibitors, increasing the
IC50 of Mut101 on IN-LEDGF interaction inhibition
from 0.097 to 0.68 μM (Figure 1E-F). Mut101 and
several of these inhibitors were co-crystallized with the
IN-CCD dimer, showing that their binding pocket on
IN corresponds to the LEDGF-binding site (Figure 2A).
Data collection and refinement statistics are given on
Additional file 1: Table S1. Two Mut101 molecules bound
to the IN-CCD dimer (Additional file 1: Figure S1A).
The ligand was found to be in a pocket surrounded by
hydrophobic residues on one side, an acidic region on
the other side and basic residues at the bottom of the
pocket (Additional file 1: Figure S1B). Three hydrogen
bonds link the carboxylic acid group of Mut101 and
the protein (Figure 2A), one with the hydroxyl group of
the side chain of Thr 174, and two with the amino group
of the main chain of His 171 and Glu 170. In addition
Mut101 was found to interact with two water molecules
(Additional file 1: Figure S1C). The IN-CCD structures
with and without Mut101 were superimposed. We found
Table 1 Structure and activity of IN-LEDGF inhibitors designed in this study
Compound Structure MW(g/mol)
Biochemical assays MT4 assays
CCD-IBD
IC50 (μM)
IN-LEDGF
IC50 (μM)
IN ST IC50 (μM)
plateau (%)
NL4-3
EC50 (μM)
HxB2
EC50 (μM)
CC50 (μM)
Mut029* 391 1.7 2.5 NT 3.8 3.8 >50
Mut047* 390 3.8 7.9 0.88
70%
16 19 >50
Mut049 355 18 3.5 0.18
56%
2.0 0.75 >50
Mut062* 394 2.7 3.1 0.54
73%
3.3 1.3 >50
Mut063
O
O
O
O
OH
433 >100 >100 >100 ND >50 NT >50
Mut075 353 14 4.0 NT 3.4 1.0 >50
Mut101* 410 0.23 0.20 0.17
66%
0.54 0.092 >50
Structure, molecular weight, and activities of compounds. NT = not tested. *compounds that have been co-crystallized with IN-CCD; IC50 = concentration required
to inhibit CCD-IBD interaction, IN-LEDGF interaction or IN strand transfer activity by 50%; EC50 = concentration required to inhibit HIV-1 infection of MT4 cells by 50%;
CC50 = concentration required to inhibit MT4 cell viability by 50%.
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Figure 1 Inhibition of IN-LEDGF interaction, correlation with ARV activity and LEDGF competition for IN binding. (A) IN-CCD/LEDGF-IBD
interaction inhibition dose–response curves of the compounds listed in Table 1. Data represent the means of six independent experiments with
standard deviations shown as error bars. (B) Log-log correlation plot between IC50 of CCD-IBD interaction inhibition and EC50 of ARV activity for
MT4 cells infected by HxB2 HIV-1. A subset of 51 Mut101 series compounds was studied (R2 = 0.77). (C) IN-LEDGF/p75 interaction inhibition
dose–response curves. Data represent the means of three independent experiments with standard deviations shown as error bars. (D) Log-log
correlation plot between IC50 of IN-LEDGF/p75 interaction inhibition and EC50 of ARV activity as in (B) (R
2 = 0.88). (E) IN-LEDGF/p75 interaction
inhibition dose–response curves for Mut101 at various LEDGF/p75 competing concentrations ranging from 7.5 nM to 480 nM. Data represent the
means of two independent experiments done in quadruplicate with standard deviations shown as error bars. (F) Correlation plot between
LEDGF/p75 concentration and IC50 of Mut101 IN-LEDGF interaction (R
2 = 0.94).
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which contrasts with previously reported IN-CCD/LED-
GIN or tBPQA co-structures where no differences were
found [18,36,37]. The first region of structure difference
encompasses alpha helices 115–122 and 123–134 as
well as the alpha helix 92–98. Surprisingly, a strong
displacement of the loop encompassing residues Ile 89,
Pro 90 and Ala 91 was found to affect the two monomers
(Figures 2C). The same differences have been observed
with the IN-CCD/LEDGF-IBD structure [11]. The second
region of difference is in the Mut101 binding pocket
where the side chains of Gln 95 and Glu 170 are displaced
(Figure 2D). These long range structural changes are
affecting the IN catalytic site, see movie in supplementary
(Additional file 2, the catalytic site is at the position of the
magnesium ion shown as a green sphere), which explains
the decrease in the 3′ processing activity in the Mut101
bound form of IN. Upon ligand binding, conformational
changes in the dimerization interface lead to stronger
interactions, stabilizing the IN dimer. For example, the
side chains of Gln 96 and Lys 173 are interacting in thepresence of Mut101 as shown in Figure 2E-F and in the
supplementary movie (Additional file 2). These interactions
strongly stabilize the IN dimeric form and explain the
multimerization effect with the binding of Mut101.
Moreover, the structural changes at the IN surface upon
Mut101 binding most probably affect IN interaction with
protein cofactors and DNA. Altogether these results
confirm and explain at the atomic level the allosteric
effect of the IN/LEDGF interaction inhibitor.
Effect of IN-LEDGF inhibitors on IN strand transfer and 3’
processing activities is independent of LEDGF
We found that these compounds inhibited the IN strand
transfer activity as quantitated by ELISA assay (Figure 3A),
in agreement with previously reported data, with IC50
values in a similar range to those found for inhibition
of the IN-LEDGF interaction (Table 1). Activity in the
concentration range studied (up to 100 μM) was always
partial (reaching a plateau at 56-73% inhibition), which
contrasts the full inhibition obtained using Raltegravir.
In contrast with data reported by Christ et al. [35],
Figure 2 Structure of Mut101 bound to IN-CCD. (A) Zoomed view highlighting the hydrogen bonds between Mut101 (in green) and the
IN-CCD dimer (in gold and blue). (B) Superimposition of the IN-CCD structures solved with (gold) and without (blue) Mut101. Two regions show
significant differences and are highlighted by a white rectangle. (C-D) Enlargement of the two regions C and D showing the conformational
changes upon ligand binding. (E-F) Solvent accessible surface coloring of IN monomers in red and gold, in absence (E) and in presence (F) of
MUT101. Nitrogen atoms are in blue, oxygen in red and sulfur in yellow. Mut101 is represented in cyan. The position of K173 and E96 are shown
on each monomer. The figure was made using PyMOL [73].
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before or after DNA in this strand transfer assay, did
not result in full inhibition (data not shown). This partial
and weaker inhibition than that of INSTIs, was confirmed
using a typical assay with radioactive oligonucleotide and
gel analysis of the strand transfer products (Figure 3E-F).
Mut101 and Raltegravir had an additive inhibitory effect
on IN strand transfer activity: there was no significant
change in the IC50 value of Raltegravir in the presence of a
saturating concentration of Mut101 (52 nM vs. 58 nM
when both present; Student′s t-test: p = 0.48; Figure 3B).
This IN strand transfer inhibition was found regardless
of whether or not the donor DNA was preprocessed
[36]. Inhibition of IN 3′ processing activity was reported
for some INLAIs [37]. We found that increasing con-
centrations of Mut101 or BI-D lead to a slight decrease
in the 3′ processing efficiency (with a maximum of 25-30%
inhibition, Figure 3C-D), but their inhibition of the IN
strand transfer reaction was more important. (Figure 3E-F).
IN-LEDGF inhibitors enhance the IN-IN interaction
We evaluated the ability of IN-LEDGF inhibitors to
promote modifications in the interaction between INsubunits as these inhibitors act at the IN dimer inter-
face. We designed an HTRF-based assay to monitor the
interaction between His6-IN/Flag-IN subunits. In the
presence of compound concentrations the HTRF signal
corresponding to the His6-IN/Flag-IN interaction was
more than twice as strong as the signal obtained in the
absence of compound (Figure 4A). The concentration
required to activate the IN-IN interaction by 50% (AC50)
closely correlated with the inhibition of the IN-LEDGF
interaction and the antiretroviral activity EC50 (Figure 4B).
Raltegravir had no effect on either the IN-LEDGF
interaction or IN-IN interaction (data not shown).
These results are in agreement with previously reported
observations on the effect of some LEDGINs and tBPQAs
on IN-IN interactions [35-37]. In order to determine if
this enhancement of IN-IN interaction corresponds to
a change toward higher IN oligomerization state, we
performed size exclusion chromatography of IN that
has been or not preincubated with Mut101 or with the
related compound BI-D. As shown in Figure 4C-D and
on Additional file 1: Table S2 for the elution volumes
of the different peaks, while IN wt in the absence of
INLAIs behaves as an IN dimer (blue peaks), pre-
AC
E
B
D
F
Figure 3 Effect of INLAIs on IN catalytic activities. (A-B) IN strand transfer inhibition in ELISA assay: (A) The IN strand transfer inhibition of
compounds listed in Table 1 is compared to inhibition with Raltegravir (RAL). Data represent the means of three independent experiments with
standard deviations shown as error bars. (B) Additive effect of Mut101 and Raltegravir on IN strand transfer inhibition. Comparison of dose–response
curves of Raltegravir alone and Raltegravir in the presence of 10 μM Mut101. Mean of triplicate with standard deviation. Dotted lines highlight the IC50
of Raltegravir in both conditions (difference not significant, Student’s t-test p = 0.48). (C-D) IN 3′ processing inhibition by Mut101 and BI-D assayed
using standard radioactive assay: increasing concentration of Dolutegravir (DTG, from 3.3 to 100 nM), BI-D or Mut101 (from 0.01 to 100 μM) were
used. The relative cleavage efficiency is reported for BI-D and Mut101 (D), and corresponds to the ratio between the product (19 bp) and the substrate
(21 bp) converted to % inhibition. DTG resulted in 16% inhibition at 100 nM. (E-F) IN Strand transfer inhibition activity of Mut101 and BI-D
assayed using standard radioactive assay: increasing concentration of DTG (from 0.3 to 10 nM), BI-D or Mut101 (from 0.01 to 100 μM) were used.
The relative strand transfer efficiency is reported for BI-D and Mut101 (F), and corresponds to the ratio between the strand transfer products
depicted on the autoradiography and the substrate (19 bp), converted to % inhibition. DTG has an IC50 of 2.7 nM.
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oligomerization state (red peaks), that likely corresponds
to a partial formation of IN tetramer. Raltegravir had no
effect (data not shown). In contrast with some LEDGINs
previously described [18], Mut101 and BI-D conserved full
ARV activity on the HIV-1 mutant IN A128T and full
in vitro activity on the IN NL4-3 A128T protein mutant.
So, we performed similar experiments with this IN A128T
protein. As shown in Figure 4E-F and on Additional file 1:
Table S2, the higher IN oligomerization state promoted by
binding of Mut101 or BI-D to the LEDGF binding pocket,
corresponds clearly to a shift from IN dimer (blue peaks)
toward IN tetramer (red peaks). This slight difference
between the results obtained with IN wt and the INA128T mutant is likely due to a more soluble behavior
of the IN A128T mutant protein compared to IN wt. In
both experiments we did not observe the formation of
IN aggregates of very high molecular weight, except for
a very minor peak (peak 7) after incubation of IN A128T
with Mut101, which elution volume (see Additional file 1:
Table S2) could correspond to the formation of such
aggregates. However, we cannot exclude that insoluble
aggregates are formed but do not enter the gel filtration
matrix.
Altogether, wee confirmed that, in addition to their
ability to inhibit IN-LEDGF, IN-LEDGF inhibitors are
allosteric inhibitors of IN and promote IN confor-
mational change by binding to the LEDGF-binding
A C D
B E F
Figure 4 Effect of INLAIs on the oligomeric state of IN. (A-B) IN-IN HTRF interaction: (A) IN-IN interaction activation dose–response curves.
Data represent the means of three independent experiments done in duplicate with standard deviations shown as error bars. (B) Correlation
between AC50 of IN-IN interaction and EC50 of ARV activity on MT4 cells infected with HxB2 HIV-1 (R
2 = 0.78). This study used 21 of the set of 51
compounds. AC50 = concentration required to activate IN-IN interaction by 50% of the maximum effect. (C-F) Size exclusion chromatography
of IN: Binding of INLAIs BI-D or Mut101, to IN NL4-3 wt (C-D) or IN NL4-3 A128T (E-F), promotes a shift toward higher IN oligomeric state,
independently of LEDGF. Blue peaks: elution of IN wt and IN A128T in the absence of compound. Red peaks: elution of IN wt and IN A128T in
the presence of BI-D (C, E) or Mut101 (D, F).The elution volume and identification of each peak (numbered 1 to 7) are indicated in supplementary
table S2.
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to IN [16,46].Mut101 behaves as an inhibitor of integration in
time-of-addition experiments
We performed a time-of-addition experiment (TOA) to
identify the HIV-1 replication cycle step that is blocked
by Mut101. We used Mut101 at a saturating concentration
(25 μM) and single-cycle infection kinetics with VSV-G-
pseudotyped Δenv HIV-1 NL4-3 expressing luciferase as a
measure of infection. The kinetics of decreased activity
after Mut101 addition were very similar to that observed
with Raltegravir, but different to those of Nevirapine,
suggesting that Mut101 at saturating concentration be-
haved as an inhibitor of integration (Figure 5A). This is
in full agreement with data reported previously on
LEDGINs and tBPQAs [18,36]. The replication cycle
analysis by quantitative PCR confirmed that Mut101
inhibited the integration of the proviral DNA (Figure 5C)
but not the production of proviral DNA at reverse
transcription (Figure 5B).Mut101 remains fully active against HIV-1 mutants that
are resistant to INSTIs and other anti-HIV drugs
Mut101 was tested against a panel of virus mutants
harboring, in an NL4-3 background, some of the strongest
resistant mutations to INSTIs and other classes of ARV
drugs used in clinics [47]. These mutants are listed on
Table 2. The activity of Mut101 and reference compounds
was quantified by the fold change (FC) ratio between EC50
on resistant virus and EC50 with the wild type (wt) – a
measure of compound efficacy on resistant mutant virus.
Mut101 had an FC ratio of 1 or lower against all resistant
viruses contrasting the results with reference compounds
(Table 3). This demonstrates that Mut101, as IN-LEDGF
inhibitor, is a candidate for a novel class of drugs that can
act on viruses resistant to those currently used in clinics,
including INSTIs.
Unlike INSTIs, the Mut101 series of compounds are more
potent when assayed with replicative HIV-1 than with
non-replicative pseudotyped virus
The ARV activity of a drug can be assessed using different
assays. Multiple round infection using a replication-
A B C
Figure 5 Time of addition experiment and qPCR analysis. (A) Time-of-addition (TOA) experiment in single-round infection assay of MT4 cells
infected with VSV-G-pseudotyped HIV-1 Δenv-Luc NL4-3. Each compound (Mut101, Nevirapine (NVP) or Raltegravir (RAL)) was added at the indicated
times post-infection. Infection was measured by luciferase assays. Relative inhibition (%) was determined by comparison with the control. qPCR analysis
of (B) the formation of proviral DNA at reverse transcription, and (C) the integration of the proviral DNA in the host cell genome after compound
treatment as indicated. NI: not infected. Data represent the means of quadruplicates with standard deviations shown as error bars.
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drug, but cannot give an indication as to which step of
the viral replication cycle is blocked. All classes of
drugs are found fully active in multiple round infection
assays. In contrast, in single-round infection, replication-
defective Δenv viruses pseudotyped with an exogenous
envelope (VSV-G) can complete viral replication only up
to integration. This enables drugs like RT or IN inhibitors
(fully active because they act early during the replication
cycle, before or at integration) to be distinguished from
drugs such as protease inhibitors that act late after inte-
gration (inactive in the single cycle assay) (see Table 4).
Drugs that act early during reverse transcription
(such as AZT and Nevirapine), or at integration (such
as Raltegravir) showed ARV activity that is similar or
slightly better in single-round (SR) infection assays than in
multiple round (MR) infection assays (an EC50 SR/EC50
MR ratio of 1 or lower; Table 4). IN-LEDGF inhibitors,
as allosteric inhibitors of HIV-1 integrase, were expected
to behave similarly to Raltegravir with a SR/MR ratio
close to 1. Intriguingly this was not the case. In contrast,
Mut101 and the other compounds of this study were
much more potent in MR than in SR infection assay
with EC50 SR/EC50 MR ratios always much higher
than 1 and up to 18 for Mut101 (Table 4). Mut101 and
the other IN-LEDGF inhibitors also differ from protease
inhibitors (PIs) since PIs are active only in MR and
completely inactive in SR assays. The Mut101 series of
IN-LEDGF inhibitors have an unprecedented mixedTable 2 Resistant viruses used in this study
Resistance mutations to
Protease inhibitor (PI)
Nucleoside RT inhibitor (NRTI)
Non-nucleoside RT inhibitor (NNRTI)
Nucleoside and non-nucleoside RT inhibitor (Multi-drug)
Integrase strand transfer inhibitor (INSTI)
Mutant viruses used in this study that are resistant to PIs, NRTIs, Multi-drugs (NRTI +profile with moderate ARV activity in SR and more
potent activity in MR infection assays. The two dose–
response curves of Mut101 ARV showed that there
was no or minimal activity detectable in the SR assay
at the concentration resulting in maximum MR activity
(Figure 6A). This suggests that the contribution of inte-
gration inhibition (estimated by SR assay) to Mut101
overall ARV activity is minimal at this concentration.
This contribution becomes significant only at much
higher concentrations, such as those used for TOA
experiments. Previous infection experiments studying
LEDGINs and tBPQAs ARV activity were performed
mostly in MR assay. We analyzed the behavior of a
tBPQA, racemic BI-D [48] (structure shown in Additional
file 1: Figure S2), to determine if the behavior of the
Mut101 compound series is shared by other LEDGINs
and tBPQAs. We found a similar discrepancy between
high EC50 in SR (2.4 μM) and much lower EC50 (0.17 μM)
in MR assay.
Mut101 also promotes a post-integration block producing
defective HIV-1 progeny virions
The discrepancy between potent ARV activity in MR
assays and moderate activity in SR assays, distinguishes
Mut101 from INSTIs that specifically block HIV integra-
tion. One explanation could be that Mut101 treatment
results in a second ARV activity at a late stage of the
replication cycle, post-integration. We used the HeLa-LAV
system in which the HeLa cell line has been transduced byGene Mutations
Protease L10R, M46I, L63P, V82T, I84V
RT M41L, D67N, T69N, K70R, T215F, K219E
RT K103N, Y181C
RT M41L, D67N, K103N, M184V, L210W, T215Y
Integrase G140S, Q148H
NNRTI), NNRTIs or INSTIs.
Table 3 EC50 fold-changes on resistant viruses
Compound EC50 (μM) EC50 fold change
NL4-3 WT PI NRTIs Multi-drug* NNRTIs INSTIs
RAL 0.007 1 1 0.5 1 374
EVG 0.003 1 0.3 0.3 1 2036
AZT 0.14 1 88 10 0.1 0.4
NVP 0.16 1 3 14 287 1
IDV 0.032 9 1 1 1 1
Mut101 0.47 1 1 1 1 1
EC50 fold change (FC) of Mut101, Raltegravir (RAL), Elvitegravir (EVG), Nevirapine
(NVP), Zidovudine (AZT) and Indinavir (IDV) (ratio of the EC50 on resistant viruses
to the EC50 on the wt virus). Data represent the mean of two independent
experiments. * contains resistance mutations against NRTIs and NNRTIs.
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is constitutively integrated in this cell line and HeLa-LAV
cells produce HIV-1 LAV virions that cannot reinfect
the cells as they do not express CD4 on their surface.
Only drugs that could block virus production at the
post-integration step of the HIV-1 replication cycle are
expected to be active in this cell line. We treated HeLa-
LAV cells with Mut101, Raltegravir, Saquinavir (SQV)
or DMSO (as a negative control). The infectivity of viruses
produced in the presence of these compounds was tested
in TZM indicator cells expressing luciferase and by
infection of MT4 cells. The design of this experiment is
schematized in Figure 6B. The amount of p24 produced
with virus treated by Mut101 was comparable to viruses
treated with Raltegravir, DMSO or Mut063 an inactive
analogue of Mut101 (Figure 6C). In contrast, luciferase
assay in TZM cells showed that Mut101 and SQVTable 4 Antiviral activities in single-round and
multiple-round infection assays
Drug NL4-3 EC50 (μM) SR/MR
ratioSingle-round Multiple-round
EFV 0.0012 ± 0.0004 0.0013 ± 0.0002 0.9
RAL 0.0025 ± 0.0003 0.0024 ± 0.0006 1
EVG 0.00042 ± 0.00005 0.00086 ± 0.0004 0.5
NVP 0.041 ± 0.008 0.086 ± 0.012 0.5
AZT 0.0025 ± 0.0003 0.0024 ± 0.0006 0.6
IDV Inactive 0.036 NA
SQV Inactive 0.013 NA
Mut029 30 ± 4 3.8 ± 1.6 8
Mut047 37 ± 2 16 ± 7 2.3
Mut049 41 ± 2 2.0 ± 0.1 21
Mut062 30% @50 3.3 ± 1.5 >25
Mut075 23% @50 3.4 ± 1.0 >25
Mut101 9.0 ± 1.5 0.49 ± 0.04 18
EC50 for the ARV activity of Mut101 compound series (tested in SR and MR
assays) and the SR/MR ratio compared to the indicated drugs. Data represent
the mean of six independent experiments.treatments resulted in strong virus infectivity defects;
viruses produced in the presence of Raltegravir, DMSO
or Mut063 had no infectivity defect (Figure 6D). These
results were confirmed by determining the cytopathic
effect of infected MT4 cells using a CellTiter-Glo® assay
(Figure 6E). The infectivity defect was not due to a
residual concentration of Mut101 used during virus
production since the virus stock was diluted 2000
times, to an inefficient concentration much below its
EC50. We can also rule out a virucidal effect of Mut101
on virus particles released in the supernatant as Mut101
was unable to inactivate free virus once released in the
supernatant of producing cells. Altogether, these results
are strongly in favor of a defect provoked at a post-
integration step by Mut101 treatment. This defect is
additional to the block at integration detected above by
the TOA experiment. Western blot using anti-p24 anti-
body did not detect any perturbation of Gag maturation
and CA p24 content in defective virions or in Mut101-
treated HeLa-LAV cell lysates (data not shown).
A post-integration defect promoted by Mut101 treatment
requires Mut101 binding to the LEDGF-binding pocket of IN
The post-integration block promoted by Mut101 cannot
be explained by impaired IN-LEDGF interaction or the
inhibition of IN catalytic activity. It could be suggested
that such a post-integration defect might be related to
an unknown Mut101 target, in addition to IN. We
generated an NL4-3 HIV-1 virus bearing the T174I
mutation in the LEDGF-binding pocket of IN to rule
out this hypothesis. We (E. Le Rouzic unpublished results)
and others [36] have selected the T174I mutation for
resistance to IN-LEDGF inhibitors: Mut101 had an
EC50 > 50 μM on this mutant compared to an EC50 =
0.49 μM on NL4-3 wt. We used Surface Plasmon Reson-
ance (SPR) to confirm that Mut101 was less able to
bind to the mutated IN-CCD T174I than to IN-CCD
wt. Mut101 bound to IN-CCD wt with high affinity
(Kd = 0.12 μM) in a similar range to the IC50 or AC50
found in HTRF assays for inhibition of the IN-LEDGF
interaction or enhancement of the IN-IN interaction,
respectively (Figure 7A). Mut101 had no significant
binding to the mutated IN-CCD T174I (Figure 7B).
HIV-1 NL4-3 wt and the NL4-3 IN T174I mutant virus
were produced by HEK293T cell transfection in the
presence of Mut101, SQV, Raltegravir, Mut063 or DMSO.
Virions were harvested and used to infect MT4 cells
(as schematized in Figure 7C); their infectivity was
tested using a cytopathic CellTiter-Glo® assay. As shown
in Figure 7D, NL4-3 wt virus (blue bars) produced in the
presence of Mut101 was inactivated and the viability of
MT4 cells infected by this virus was preserved. In contrast,
the mutant virus T174I (red bars) was insensitive to
Mut101 treatment and MT4 cells were fully infected and
A B
C D E
Figure 6 ARV activity in infection assays and effect on the infectivity of virions produced by HeLa-LAV cells. (A) Plot comparing the ARV
activity of Mut 101 tested by MR and SR infection assays (using the same concentration scale). (B) Diagram of the experimental setup used to study
infectivity of virions produced by HeLa-LAV cells that were treated with Mut101, Raltegravir, SQV, Mut063 or DMSO at the indicated concentrations.
(C) Titration of p24 harvested from HeLa-LAV cells treated with the indicated compounds. (D) Infectivity of virions harvested from HeLa-LAV cells
treated with the indicated compounds and tested by infection of TZM indicator cells and luciferase assay. (E) Infectivity of virions harvested from
Hela-LAV cells treated with the indicated compounds and tested by infection of MT4 cells and cytopathic assay using CellTiter-Glo®.
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sensitive to and inactivated by SQV treatment. Raltegravir
treatment during virus production had no effect on either
virus; these retained full infectivity which was comparable
to that observed after DMSO or Mut063 treatment.
These results demonstrate that integrase is indeed the
unique target of Mut101 for its ARV activity, both at
the integration and post-integration steps of the HIV-1
replication cycle.Discussion
IN-LEDGF allosteric inhibitors (INLAIs) are a new class
of IN inhibitors whose binding site, the LEDGF-binding
pocket, is different from the IN catalytic site targeted
by INSTIs. In this study we described new IN-LEDGF
inhibitors from the family of LEDGINs and TBPQAs.
These compounds shared multiple activities with the pre-
viously described compounds of this class. These include:
inhibition of the IN-LEDGF interaction, weak inhibition of
IN strand transfer activity (additive to that of Raltegravir)
and even weaker inhibition of IN 3′ processing activity,
IN conformational change by increased IN-IN interaction
that favors higher order oligomerization state of IN
(independent of LEDGF, with AC50 similar to the IC50found for IN-LEDGF inhibition), and a dual mode of
ARV activity at both integration and post-integration
steps of viral replication. These results define the Mut101
series of compounds like other IN-LEDGF inhibitors as
bona fide allosteric inhibitors of IN functions. Since both
catalytic activities of IN, 3′ processing and strand transfer
are dependent on the oligomeric state of IN [50], it is
likely that the shift of IN dimer toward higher order
oligomeric state of IN promoted by Mut101 or BI-D
binding, is more detrimental to the strand transfer reac-
tion rather than to the 3′ processing activity of IN.
Our co-crystallographic studies with Mut101 bound to
IN-CCD allowed us to detect conformational changes
resulting from compound binding in the binding site of
inhibitors. The structural changes observed when Mut101
is bound to IN confirm and explain the allosteric effect
of the IN/LEDGF interaction inhibitor which acts at
the post-integration steps. We evidenced a direct cor-
relation between allosteric changes with atomic details
and functional effect on IN upon Mut101 binding. Our
experiments enabled us to address important questions
regarding the unicity or multiplicity of the mechanism
of action of these inhibitors, the respective contributions
of these inhibitory activities to overall ARV activity, and
the specific mode of action of these new ARV agents.
AC D
B
Figure 7 Binding to IN-CCD wt, T174I mutant, treatment during production of wt and T174I mutant viruses. (A) Binding kinetics of
Mut101 to IN-CCD wt. Serial dilutions of Mut101 (between 9.8 nM and 5 μM) were injected on immobilized GST-Flag-CCD wt. (B) Binding kinetics
of Mut101 to IN-CCD T174I. Serial dilutions of Mut101 (between 1.3 μM and 5.0 μM) were injected on immobilized GST-Flag-CCD T174I. (C) Diagram of
the experimental setup to study the infectivity of NL4-3 wt and IN T174I virions produced after transfection of 293 T cells. The indicated compounds
were added during virus production for 48 h. Supernatants were tested for virus production by p24 assay, and for virus infectivity. (D) Infectivity of wt
NL4-3 (blue bars) and IN T174I NL4-3 mutant (red bars) virions harvested from 293 T transfected cells after treatment with the indicated compounds
and infection of MT4 cells by cytopathic assay using CellTiter-Glo®.
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of IN strand transfer and IN-LEDGF interaction, given the
role of LEDGF in the tethering of IN to chromatin during
the integration process of HIV-1. The post-integration
block promoted by INLAIs is not in line with these
activities. This raises the possibility that these compounds
have another unrelated target in addition to the LEDGF-
binding pocket of IN. We ruled out this hypothesis
using a virus mutated in the LEDGF-binding pocket of
IN (NL4-3 IN T174I, resistant to Mut101 ARV activity)
and demonstrate that IN is indeed the target of this
post-integration defect: the lack of Mut101 binding to
the IN-CCD T174I correlated with the absence of effect
of Mut101 on the production of the NL4-3 IN T174I
mutated virus. We conclude that both the integration
and post-integration blocks promoted by INLAIs are
related to the binding of these compounds to a unique
target, the LEDGF-binding pocket of IN. This dual
inhibitory activity, at two different steps of the HIV-1
replication cycle through the same viral target, is
unprecedented for all classes of ARV drugs.We investigated the respective contributions of the
two mechanisms to the global ARV activity of these
compounds. SR infection assays reflect the activity of
an ARV compound during an early step of the HIV
replication cycle (up to integration), and MR infection
assays reflect global ARV activity. We showed that the
post-integration inhibition of the HIV-1 replication
cycle is the major mechanism contributing to global
Mut101 ARV activity. There was no or minimal ARV
activity detectable in SR infection assay at the same
Mut101 concentration that achieved 100% inhibition
of HIV-1 infection in the MR infection assay. A higher
concentration of Mut101 was required to detect ARV
activity in the SR assay since its EC50 in this format
(9 μM) was 18 times higher than its EC50 in MR infec-
tion assay (0.49 μM). TOA experiments used a Mut101
concentration (25 μM) that was high enough to permit
100% of ARV activity in the SR infection assay. Our
study demonstrates that Mut101 and the other INLAIs
of this series are not acting mainly as inhibitors of
HIV-1 integration. This is in contrast to early studies
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performed at saturating inhibitor concentration, that
suggested they act as integration inhibitors [18]. HIV-1
integrase is the unique target of Mut101 for its ARV
activity. However, the major action of Mut101 and
other related INLAIs is as post-integration inhibitors
producing defective infectious HIV-1 virions.
Mut101 displays weak activity at early stage integration
and potent activity at late stage production of defective
virions. We then explored how a compound acting on
a unique target (IN) and on a unique binding site (the
LEDGF-binding pocket), displays such a difference
between its potency on two ARV activities. The ARV
activity of Mut101 series INLAIs and their inhibition
of the IN-LEDGF interaction are clearly linked. There
is a tight correlation between their action on IN-LEDGF
interaction inhibition and their activity on IN-IN inter-
action enhancement and IN conformational change.
Further studies are required to resolve this issue. However,
some clues are provided by Wang et al., who studied
the ARV activity of a tBPQA compound (racemic BI-D)
on wt and LEDGF KO mouse cells infected with a VSV-
G-pseudotyped HIV-1 luciferase virus in SR infection
experiments [40]. The EC50 of racemic BI-D ARV activity
was between 2.4 μM and 2.9 μM when tested on wt cells
but between 0.16 μM and 0.20 μM (15 to 18 times lower)
on LEDGF KO cells, a result not significantly altered by
HRP2 disruption. In contrast, the EC50 of Raltegravir
was similar in each cell type. The authors suggest that
LEDGF, present in wt cells but not in LEDGF KO cells,
can compete with BI-D for binding to the LEDGF-binding
pocket of IN. In the presence of a LEDGF competitor in
wt cells, the concentrations of BI-D required to achieve
similar ARV activity are higher than when LEDGF is
absent in KO cells. Strikingly, we found that the EC50
of BI-D ARV activity on MT4 human cells infected with
HIV-1 NL4-3 was 2.4 μM± 0.5 in SR and 0.17 μM± 0.03
in MR infection assays. This is very similar to the result
found by Wang et al. (Table 5), although they worked with
mouse cells and we worked with human cells. The data
strongly suggest that a mechanism similar to that observed
by Wang et al. (LEDGF competition in SR assay and no
competition by LEDGF in MR assay), could explain theTable 5 BI-D anti-retroviral activity EC50
This study
Human cells
Single-round/MT4 Multiple-round/MT4
2.4 ± 0.5 μM 0.17 ± 0.03 μM
Wang et al. study [40]
Mouse cells
LEDGF +/+ WT cells LEDGF −/− KO cells
2.4 to 2.9 μM 0.16 to 0.20 μM
A comparison of BI-D ARV activity (EC50) assayed in this study (using MT4
human cells) and results reported by Wang et al. (using LEDGF WT and KO
mouse cells).difference in ARV activity we found for INLAIs assayed in
SR and MR infection assays. These data, and our in vitro
data showing that LEDGF can compete with Mut101 for
binding to IN, support the model illustrated in Figure 8
concerning the considerable difference in the potency
of INLAIs between their low ARV activity at integration
and their much higher activity inhibiting the production
of infectious particles at post-integration stages, although
both activities are due to the occupation of the same
binding site on IN. The inhibition of HIV-1 integration
by INLAIs, measured in SR infection assays, is based
on the impairment of the IN-LEDGF interaction and
allosteric inhibition of IN. This takes place in the nucleus
of HIV-1 target cells. In this cellular compartment LEDGF
is abundant and can compete effectively with INLAIs for
binding to IN, limiting ARV activity of these inhibitors at
this stage. In contrast, the activity of INLAIs at the virus
production stage, as measured in MR assays, takes place
in the cytoplasm of virus-producer cells after integration.
LEDGF, a chromatin-bound nuclear protein, is absent
from this cellular compartment and cannot compete
with INLAIs for binding to IN or to the Pol polyprotein
containing IN [42]. INLAIs are able to target both the IN
associated with incoming virions at the step of integration
in target cells (in the nucleus, in the presence of compet-
ing LEDGF) and the newly synthesized IN in producer
cells (associated with progeny virions in the cytoplasm
or at the plasma membrane, in the absence of LEDGF).
This model suggests that the activity of a protein-protein
interaction inhibitor (in this case, concerning the inter-
action between a viral and a cellular protein) is governed
not only by its intrinsic affinity for its target, but also by
the cellular compartment in which it is acting. It is the
presence or absence of the partner protein of the inhibitor
target that could, by competitive binding, negatively affect
the level of inhibitor activity.
The activity of Mut101 and other INLAIs, at the step
of integration, may be explained by impairment of IN-
LEDGF interaction and their allosteric inhibitory effect
on IN strand transfer catalytic activity. However, we
need to understand what molecular mode of action of
these compounds explains the post-integration block.
Gag maturation and CA composition of defective virions
produced in the presence of these compounds was normal
[42,43] (E. Le Rouzic unpublished results), suggesting
that there is no putative effect on maturation of the
Gag precursor. We also know that Mut101 does not
inhibit viral protease (D. Bonnard unpublished data). A
post-integration stage defect could be related to IN
conformational change resulting from compound binding
to the LEDGF-binding pocket and IN-IN interaction
enhancement ([42,43] and this study). We showed, for the
first time, that INLAIs promoted long range conform-
ational change when they bind to IN-CCD, affecting
Figure 8 Model accounting for the discrepancy between the dual ARV activities of INLAIs at integration and post-integration. The full
replication cycle of HIV is represented with steps occurring in target cells (1) separated from the steps occurring in virus-producing cells (2) by a
red line. (1) Inhibitory activity at integration and competition by LEDGF in HIV-1 target cells. LEDGF is present as a chromatin-bound protein in
the nucleus but is absent in the cytoplasm. After infection of target cells, IN associated with the entering virus (in blue) is imported into the
nucleus as part of the pre-integration complex (PIC). Mut101 and INLAIs (yellow triangles) can bind to IN, inhibiting integration by allosteric inhibition
of IN strand transfer activity and preventing IN-LEDGF complex formation. In the nucleus of target cells, LEDGF will compete with Mut101 and INLAIs
for binding to IN, thus lowering their apparent affinity for IN and counteracting their antiretroviral activity at the integration stage of the replication
cycle. (2) After integration, progeny virions are assembled in the cytoplasm and at the plasma membrane. INLAIs can bind to the Pol polyprotein
precursor containing IN or to the matured IN, in the absence of competing LEDGF. Upon binding, these inhibitors promote conformational modification
and enhancement of the IN-IN interaction resulting in IN inactivation (in red). Mut101 and INLAIs activity at the post-integration stage is stronger than
their activity at integration as there is no competition with LEDGF in the cytoplasmic cellular compartment.
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Such IN conformational change could negatively affect
the formation of the stable synaptic complex (SSC)
[37], or influence the currently undefined roles of IN
during late stages in the HIV-1 replication cycle [51].
Interestingly, it was lately reported [42-45] that treatment
by IN-LEDGF allosteric inhibitors during virus production
resulted in a defect in virion morphology with eccentric
electron-dense HIV core. Further work is required to
answer these questions and defective viruses produced
in the presence of Mut101 could be valuable tools for
these studies.
The LEDGF-binding pocket lies at the dimeric inter-
face of IN, a region crucial for the formation of an active
oligomerization state of IN required for its enzymatic
activity and specificity [52-54]. INLAIs make contacts
to both subunits of an IN dimer and promote IN con-
formational change toward inactive oligomers. These
inhibitors should therefore be considered as interfacial
inhibitors that bind selectively to macromolecular ma-
chine interfaces and often promote allosteric effects [55].Interestingly, INSTIs that bind at the interface of the IN-
DNA-Mg2+ complex [2] are also considered as archetypal
interfacial inhibitors [55].
Conclusion
The dual mode of action of Mut101 compound series, at
two different steps of the HIV replication cycle, is
unique and unprecedented in all classes of ARV drugs.
This could confer a great advantage to this class of ARV
compounds from a therapeutic point of view, provided
that clinically efficient concentrations can be reached to
inhibit also virus replication at integration. The absence
of antagonism between Mut101 compounds and INSTIs
or the other classes of drugs currently on the market
supports their potential for future ARV therapy.
Several acronyms have been proposed for this class of
compounds: LEDGIN [18], NCINI [36] and ALLINI
[37] have been suggested to underline their mode of
action either as LEDGF-IN inhibitors or as Allosteric
IN inhibitors. We would like to propose the acronym
of INLAI, standing for ‘IN-LEDGF Allosteric Inhibitor’.
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interference with LEDGF binding to IN and their powerful
allosteric inhibitory activity on IN. Our acronym links
both activities in the mode of action and highlights that
the binding site of these compounds on IN is the
LEDGF-binding pocket.
Methods
Compound synthesis
Mut029, Mut047, Mut049, Mut062, Mut063, Mut075,
and Mut101 compounds were prepared as described in
WO2012/140243A1, according to examples 20, 15, 2,
17, 9, 18 and 26, respectively [33]. Details for compound
synthesis are given in the Additional file 1. Racemic
BI-D was prepared as described in WO2009/062285A1,
according to example 41 [20].
Virology
Reference compounds
Control compounds such as Saquinavir (SQV), Indinavir
(IDV), Nevirapine (NVP), Efavirenz (EFV) and AZT were
obtained from the NIH AIDS Research and Reference
Reagent Program. Raltegravir (RAL) and Elvitegravir
(EVG) were purchased from Selleck Chemicals.
Cell culture
MT-4, TZM-bl and HeLa-LAV cells were obtained
through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH. MT-4 cells
were grown in RPMI 1640 supplemented with 10%
heat-inactivated fetal calf serum and 100 IU/mL penicillin,
and 100 μg/mL streptomycin (Invitrogen) to obtain
RPMI-complete medium. HeLa-LAV, TZM-bl and 293 T
cells (ATCC, CRL-11268) were grown in DMEM supple-
mented with 10% FCS and antibiotics. TZM-bl cells are a
HeLa modified cell line containing separately integrated
copies of the luciferase and β-galactosidase genes under
control of the HIV-1 promoter.
Virus strains and recombinant HIV-1 molecular clones
HIV-1 NL4-3 and NL4-3Δenv-luc molecular clones were
obtained from the NIH AIDS Research and Reference
Reagent Program. The SpeI-SalI fragment from pNL4-3
containing the full pol gene was cloned into the pUC18
plasmid. In vitro mutagenesis was performed with the
Pfu Turbo (Stratagene) and specific sets of primers to
engineer the RT double mutant K103N/Y181C. The
mutated fragment was validated by sequencing (Eurofins)
and cloned back into pNL4-3 to generate a HIV-1 mutant
molecular clone (used as a NNRTI-resistant virus). The
molecular clone containing L10R/M46I/L63P/V82T/I84V
mutations within the PR-coding region [56] was used
as a PR-resistant virus (PI); the clone with M41L/
D67N/T69N/K70R/T215F/K219E within the RT-codingregion [57] was used as a NRTI-resistant virus; the
clone with M41L/D67N/K103N/M184V/L210W/T215Y
within the RT-coding region [57] was used as a NRTI
and NNRTI-resistant virus (Multi-drug in this study).
PI, NRTIs and Multi-drug resistant clones were obtained
through the AIDS Research and Reference Reagent Pro-
gram. The molecular clone containing G140S/Q148H
within the IN-coding region obtained from J-F Mouscadet
[58] was used as the INSTI-resistant virus.
Viral stock
293 T (2.2 106 cells) were transfected with 6 μg pNL4–3
proviral plasmids (wild-type or drug resistant) using
X-tremeGENE 9 reagent (Roche). Cells were washed
24 h later and cell supernatants were collected 48 h
post-transfection and stored at −80°C. Single-round viral
stocks were produced by co-transfecting pNL4-3Δenv with
VSV-G envelope expression vector. Supernatants were
collected 2 days after transfection. All viral stocks were
quantified for p24 antigen using the Alliance HIV-1
p24 Antigen ELISA (PerkinElmer) and titrated to measure
the quantity of infectious particles per mL by infecting
TZM-bl indicator cells.
Antiviral assay in MT-4 cells
MT-4 cells growing exponentially at the density of 106/
mL were infected with HIV-1 strain NL4-3 at a MOI
(multiplicity of infection) of 0.001 for 2 h. The cells were
washed with PBS and aliquoted, using 100 μL fresh
complete RPMI, into 96-well white plates (Corning) in
the presence of different concentrations of compounds.
The effective concentration of compound required to
inhibit 50% (EC50) of HIV-1 replication was determined
after 5 days using the CellTiter-Glo® luminescent reagent
(Promega) to quantify cell viability.
Replication-defective-HIV assay
MT-4 cells (growing exponentially at the density of 106/mL)
were infected with VSV-G-pseudotyped NL4-3Δenv-luc at
a MOI of 0.0001 for 90 minutes. The cells were washed
with PBS and aliquoted, using 100 μL fresh complete
RPMI, into 96-well white plates (Corning) in the presence
of different concentrations of compounds. Luciferase
expression was quantified after two days using the
One-Glo™ luciferase assay (Promega).
Cytotoxicity assays
Growth inhibition was monitored in a proliferating human
T-cell line (MT-4) with different concentrations of com-
pounds. ATP levels were quantified using the CellTiter-
Glo® luminescent reagent (Promega) to measure the ability
of a compound to inhibit cell growth, an indication of
the compound’s cytotoxicity. Cytotoxicity was evaluated
at either day 2 or day 5.
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MT-4 cells in a 96-well microtiter plate (105 cells per
well) were infected with pseudotyped HIV-1 NL4-3
strain at a MOI of 0.001. Compounds were added to
single-round infection assays at different time points
after infection (0, 2, 3, 4, 5, 6, 8 and 24 h). RAL, NVP
and Mut101 were added at 80 nM, 2 μM and 25 μM,
respectively. This corresponded to between three and ten
times their EC50 as determined by a drug susceptibility
assay (CT-Glo).
Quantification of viral cDNA by real-time PCR
Prior to infection, viral stocks were treated 1 h at 37°C
with 100 U per mL of DNAseI (Roche Applied Science).
MT4 cells (6x106) were infected with virus at MOI =
0.001. At 7 h, 24 h and 48 h post-infection, cells were
harvested, washed twice in PBS and DNA was extracted
using the QIAamp Blood DNA Minikit (Qiagen). Quan-
tifications of viral DNA were performed by real-time
PCR using the LightCycler 480 system (Roche Applied
Science). Primers, probes, and PCR run conditions were
described previously [59]. The copy number of HIV-1
late reverse transcription product (LRT) was determined
using standard curves obtained by amplification of cloned
DNA containing the matched sequences. The copy
number of integrated HIV-1 DNA was determined in
reference to a standard curve generated by concomitant
two-stage PCR amplification of a serial dilution of the
standard HeLa HIVR7-Neo cell DNA [59]. Copy numbers
of each viral form were normalized with the number of
cells obtained by the quantification by PCR of the β-globin
gene according to the manufacturer instructions (Roche
Applied Science).
Molecular biology and biochemistry
Constructions of epitope-tagged proteins
The His6-LEDGF plasmid has been previously described
[60]. The plasmid encoding GST-Flag-IBD/LEDGF was
constructed by cloning the LEDGF DNA sequence
(encoding residues 342 to 507) in fusion with the Flag
epitope into pGEX-2 T (GE Healthcare). His6-IN plasmid
corresponds to pINSD.His and has been previously
described [61]. The IN A128T mutant was generated
by site-directed mutagenesis from pINSD.His. The full
length Flag-tagged integrase sequence from NL4-3
was PCR amplified and cloned between the BamHI
and XhoI restriction sites of a pGEX-6P1 vector (GE
Healthcare) to generate the expression plasmid GST-
Flag-IN. His-CCD and GST-Flag-CCD were obtained
by cloning the integrase region (residues 50 to 202,
encoding the catalytic core domain) from pINSD.His.
Sol [62] into pET15b and pGEX-2 T-Flag, respectively.
CCD contains the F185K mutation which greatly
improves the solubility of the recombinant protein.The CCD T174I mutation was introduced into the
His-CCD plasmid by site-directed mutagenesis.
Purification of recombinant proteins
Frozen cells pellets from one liter culture were resus-
pended in 3.5 mL of integrase buffer (50 mM HEPES
pH 7.5, 1 M NaCl, 7 mM CHAPS, 5 mM MgCl2, 2 mM
β-mercaptoethanol, 10% glycerol) (for full length inte-
grase) or the same buffer in a two-fold water dilution
(for integrase CCD), containing Complete™ protease
inhibitor cocktail (Roche) and benzonase (Sigma). Cells
were disrupted using 25 g - 30 g, 150–212 μm glass
beads (Sigma) and vortexed at 4°C for 10 min. Glass
beads were washed three times with 15 mL extraction
buffer and whole cell lysate was centrifuged at 109,000 g
(Rmax) for 1 h at 4°C in a Beckman XL80K ultracentrifuge.
His6-tagged IN wt or A128T, or His6-tagged IN-CCD
lysate was loaded at 3 mL/min on a 5 mL His-Trap FF
crude column (GE Healthcare) previously equilibrated with
integrase buffer or CCD buffer, respectively, containing
20 mM imidazole. Samples were washed until OD280nm
returned to baseline and bound proteins were then eluted
using a 20 to 500 mM imidazole gradient over 20 column
volumes. Pooled fractions were concentrated to 2.5 mL
using Amicon Ultra 15™ 10 K centrifugal filter devices
(Millipore) at 4,000 g and 4°C. Concentrated protein
was loaded on a Superdex 200 16/600 PG column (for
full length IN) or a Superdex 75 16/600 PG column (for
IN-CCD) (GE Healthcare), previously equilibrated with
integrase buffer at 4°C. Chromatography was performed
at 4°C. The presence of His6-Tag IN/CCD in collected
fractions was assessed by electrophoresis on NuPAGE
Bis-Tris 10% acrylamide gels with MES as the electro-
phoresis buffer (Invitrogen). Proteins were stained
using Imperial Protein StainTM (Thermo Scientific Pierce).
Pooled fractions from Superdex200 or Superdex75 separ-
ation were concentrated and stored at −80°C until further
use. GST-tagged Flag-CCD and GST-tagged Flag-IBD ly-
sates were loaded at 0.25 mL/min on a 20 mL Glutathione
Sepharose 4 Fast Flow (GE Healthcare) column. Bound
proteins were eluted using integrase CCD buffer with
20 mM reduced glutathione. Purification was completed
as described above. Flag-IN was prepared from a GST-
Flag-IN fusion protein using the pGEX-6P expression sys-
tem (GE Healthcare). After adsorption to the Glutathione
Sepharose 4 Fast Flow column, protein corresponding
to the 1 liter culture extract was digested by 250 units
of PreScission Protease (GE Healthcare) for 16 hours at
4°C. Cleaved protein was eluted by restarting the buffer
flow over the column. Purification was carried out by
gel filtration on Superdex 200, as described above.
rGST was purified on Glutathione Sepharose 4 Fast
Flow and Superdex 75 16/600 PG columns as described
above but using a PBS buffer.
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All HTRF® conjugated monoclonal antibodies were
purchased from Cisbio Bioassays. IN-CCD/LEDGF-IBD
HTRF® assay was performed in 384-well low volume
black polystyrene plates (Corning) in CCD-IBD assay
buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 2 mM
MgCl2, 0.4 M KF, 0.1% bovine serum albumin, 1 mM
DTT). 2 μL of 3-fold serial dilutions of inhibitory com-
pound in 25% DMSO were preincubated for 30 min at
room temperature with 8 μL of IN-CCD mixture (75
nM His6-IN-CCD, 17 nM XL665-conjugated anti-His6
monoclonal antibody). Then, 10 μL of LEDGF-IBD
mixture (20 nM GST-Flag-LEDGF-IBD, 1.8 nM Europium
cryptate-labelled anti-GST monoclonal antibody) were
added and the plate was incubated for 2.5 h at room
temperature before reading the time-resolved fluorescence
in a PHERAstar Plus (BMG Labtech) with HTRF module
(excitation at 337 nm, dual emission at 620 nm and
667 nm). The HTRF ratio was converted to % inhibition
and analyzed by fitting with a sigmoidal dose–response
equation with Hill slope to determine the compound IC50.
HTRF®-based IN-LEDGF interaction assay
IN-LEDGF HTRF® assay was performed in 384-well
low volume black polystyrene plates (Corning) using
IN-LEDGF assay buffer (25 mM Tris–HCl pH 7.4,
150 mM NaCl, 2 mM MgCl2, 0.4 M KF, 0.1% Igepal
CA-630, 0.1% bovine serum albumin, 1 mM DTT).
2 μL of 3-fold serial dilutions of inhibitory compound
in 25% DMSO were preincubated for 30 min at room
temperature with 8 μL of IN mixture (50 nM Flag-tagged
IN, 17 nM XL665-conjugated anti-Flag M2 monoclonal
antibody). 10 μL of LEDGF mixture (60 nM His6-tagged
LEDGF/p75, 1.5 nM Terbium cryptate-labelled anti-His6
monoclonal) were added and the plate was incubated
for 2.5 h at room temperature before reading the time-
resolved fluorescence in a PHERAstar Plus with HTRF
module (excitation at 337 nm, dual emission at 620 nm
and 667 nm). The HTRF ratio was converted to % inhib-
ition and analyzed by fitting a sigmoidal dose–response
equation with Hill slope to determine the IC50 of the
compound.
For the LEDGF competition assay, an IN-LEDGF assay
was performed with various concentrations of His6-LEDGF
in the LEDGF mixture (from 15 nM to 0.96 μM).
HTRF®-based IN multimerization assay
IN-IN HTRF® assay was performed in 384-well low vol-
ume black polystyrene plates (Corning). 2 μL of 3-fold
serial dilutions of inhibitory compound in 25% DMSO
were preincubated for 30 min at room temperature
with 4 μL of 125 nM Flag-IN dilution. 4 μL of 125 nM
His6-IN were added and the plate was incubated for
3 h at room temperature to allow IN subunit exchangeand multimerization. This step was performed in IN2
buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 2 mM
MgCl2, 0.005% Tween-20, 0.1% bovine serum albumin,
1 mM DTT). 10 μL of revelation mixture (1.1 nM
Europium cryptate-labelled monoclonal anti-Flag M2
antibody and 13 nM XL665-labeled anti-His6 monoclonal
antibody in IN2 buffer supplemented with 0.8 M KF) were
added and the plate was incubated for 2 h at room
temperature before reading the time-resolved fluorescence
in a PHERAstar Plus with HTRF module (excitation at
337 nm, dual emission at 620 nm and 667 nm). The
HTRF ratio was converted to % activation and analyzed
by fitting a sigmoidal dose–response equation with Hill
slope to determine the AC50 of the compound and the
activation plateau.
IN strand transfer ELISA assay
IN strand transfer ELISA assay has been adapted from
[63]. The strand transfer reaction was performed in
96-well V bottom polypropylene microplates (Greiner
Bio-One) containing 4 μL of 3-fold serial dilutions of
compound or 25% DMSO. 16 μL of IN mixture (20 mM
HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT, 0.50 μM
His6-IN) was added. After a 15 min preincubation,
20 μL of substrate oligonucleotide mixture (0.20 μM
Biotin-LTR preprocessed donor DNA, 0.20 μM Digoxi-
genin (DIG)-Target DNA) was added and the plate was
incubated for 2 h at 37°C. The reaction was stopped by
addition of 60 μL stop mixture (20 mM Tris–HCl
pH 7.6, 0.4 M NaCl, 10 mM Na2EDTA, 0.1 mg/mL salmon
sperm DNA) and the volume transferred to Reacti-Bind
high-binding capacity streptavidin-coated white plates
(Thermo Scientific Pierce). After 1 h incubation at room
temperature under gentle shaking, integrase and unjoined
DNA were removed by three washes with 200 μL wash
solution 1 (30 mM NaOH, 0.2 M NaCl, 1 mM Na2EDTA).
100 μL of 2000-fold diluted HRP-conjugated anti-DIG
Fab (Roche Applied Science) was added and the plate
was incubated for 1 h at 37°C. Unbound antibody was
removed with wash solution 2 (PBS pH 7.4, 0.05% Tween-
20, 0.1% bovine serum albumin), 100 μL of SuperSignal
Femto ELISA substrate (Thermo Scientific Pierce) was
added and chemiluminescence was immediately read in
a PHERAstar Plus with LUM-plus module. The signal,
converted to % inhibition, was analyzed by fitting a
sigmoidal dose–response curve to determine IC50 and
the inhibition plateau.
IN 3′ processing and strand transfer radioactive assays
Sequences of the different oligonucleotides (ODN) sub-
strates are U5B: 5′-GTGTGGAAAATCTCTAGCAGT-
3′, U5A: 5′- ACTGCTAGAGATTTTCCACAC-3′ and
U5B-2: 5′-GTGTGGAAAATCTCTAGCA-3′. ODNs were
purchased from Eurogentec and further purified by elec-
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activity assays, ODNs (U5B and U5B-2) were radiolabelled
with T4 polynucleotide kinase (New England Biolabs)
and γ[32−P]ATP (3000 Ci/mmol) (Amersham), and purified
on a Sephadex G-10 column (GE Healthcare). Double-
stranded ODNs (U5B with U5A and U5B-2 with U5A
used for 3′-processing and strand transfer reactions, re-
spectively) were obtained by mixing equimolar amounts of
complementary strands in the presence of 100 mM NaCl.
IN activity assays – 3′-processing, strand transfer – were
carried out at 37°C with the full-length HIV-1 IN, in a
buffer containing 10 mM HEPES (pH 7.2), 1 mM
DTT, 7.5 mM MgCl2 in the presence of 6.25 nM DNA
(3′-processing) or 12.5 nM DNA (strand transfer) as
described previously [64]. For negative control, 100 mM
Na2EDTA was added to the reaction before incubation.
Products were separated by electrophoresis in denaturing
16% acrylamide/urea gels. Gels were analysed with a
Molecular Dynamics STORM phosphoimager and quanti-
fied with ImageQuant™ 4.1 software.
Size exclusion chromatography (SEC) experiments with IN
liganded with Mut101 and BI-D compounds
SEC was performed with a Superdex 200 10/300 GL col-
umn (GE Healthcare) using a flow-rate of 0.4 mL/min in
buffer containing 50 mM HEPES, pH 7.5, 1 M NaCl,
7 mM CHAPS, 5 mM MgCl2, 10 mM DTT, 10% glycerol
at room temperature. His6-IN wt (21 μM) or His6-IN
A128T (40 μM) was incubated for 10 min with 100 μM
BI-D or Mut101 before injection on the column. Protein
elution was monitored at 280 nm.
Biacore experiments
Experiments were carried out using a Biacore 3000
instrument (GE Healthcare) at 25°C. An anti-GST anti-
body (GST Capture Kit, GE Healthcare) was immobilized
on two flow-cells of a CM5 sensor chip by amine coupling
according to the recommendations of the manufacturer.
GST-Flag tagged IN CCD proteins (wild type and T174I
mutant) at 68 μg/mL in HBS-EP buffer (GE Healthcare)
were captured on one flow-cell (8 min injection at 10 μL/
min) while recombinant GST (60 μg/mL in HBS-EP
buffer, 8 min injection at 10 μL/min) was injected on
the other flow-cell and used as a reference. Kinetics
experiments with Mut101 were carried out at 60 μL/min
with a 3 min injection of each dilution of the compound
in HBS-EP followed by 10 min dissociation. Sensorgrams
were evaluated using BiaEvaluation 3.2 software.
Structural studies
Crystallization was performed by the hanging-drop vapor-
diffusion method at 297 K in 24-well plates. The catalytic
domain (CCD) of HIV-1 IN with mutation F185K was
expressed and purified as previously described [62]. Priorto any crystallization experiment, the protein was sim-
ultaneously dialyzed and concentrated at 277 K with an
Amicon Ultra-10 device (Millipore) equipped with a
10 kDa cut-off dialysis membrane. The dialysis solution
was 50 mM MES-NaOH pH 5.5, 50 mM NaCl and
5 mM DTT. The protein was concentrated to between
3 mg/mL and 5 mg/mL.
Each hanging-drop consisted of 3 μL protein solution
and 3 μL reservoir solution, with 500 μL reservoir solution
in the well. Initial screening was carried out using Qiagen
kits (Classics & JCSG+) and positive hits were then
optimized. The optimized reservoir solution consisted
of 1.16-1.36 M ammonium sulfate, 50 mM sodium
cacodylate-HCl pH 6.5. The crystals grew to approximate
dimensions of 0.2 x 0.2 x 0.4 mm within one week. They
were soaked with the Mut101 ligand for 5 days before
data collection by adding a 10 mM stock solution of
the inhibitor to the drop. The crystals were plunged in
oil (FOMBLIN Y LVAC 14/6 from Aldrich) for a few
seconds and cryo-cooled in a stream of liquid nitrogen
at 100 K. All data were collected at a temperature of
100 K and processed with XDS [65]. All diffraction data
were collected using a Pilatus 2 M detector on beamline
X06DA (PXIII) at the Swiss Light Source, Paul Scherrer
Institut, Villigen, Switzerland. Structure determination
was carried out using the CCP4 suite of programs [66].
The structures of the integrase, both in complex with the
Mut101 inhibitor or not, were determined by molecular
replacement using the program MOLREP [67] and PDB
entry 1BHL [68] as the starting model. The models were
built manually using the program Coot [69] and refined
with the program REFMAC [70]. Arp/Warp [71] was used
for the automatic ligand [72] and water molecule fitting.
Structures and structure factors have been deposited in
the PDB with codes 4LH4 (IN CCD) and 4LH5 (IN CCD
with Mut101 inhibitor).
All experiments have been performed under Authoriza-
tion Number 5606 CA-I, assigned by the French Ministry
of Research for work with genetically modified organisms.
Additional files
Additional file 1: Additional methods, figures and tables.
Additional file 2: The movie was generated with PyMOL [73]. The
intermediate structures between the initial and final state where generated
using the morphing option in Pymol. The two IN monomers are colored in
red and gold. The magnesium ion is represented as a green sphere and the
coordinating residues of the magnesium and in the Mut101 pocket are
represented in sticks. The solvent accessible surface coloring is in red and gold
for the carbon atom of the corresponding monomer with the nitrogen in
blue, the oxygen in red and sulfur in yellow. Mut101 is represented in cyan.
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